{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:08:30Z","timestamp":1790111310733,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jfma.2026.09.018","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:08:36Z","timestamp":1789592916000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Consensus on gene therapy for spinal muscular atrophy in Taiwan"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1735-1101","authenticated-orcid":false,"given":"Yuh-Jyh","family":"Jong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8802-5728","authenticated-orcid":false,"given":"Yin-Hsiu","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7391-8715","authenticated-orcid":false,"given":"Wen-Chen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chin","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Rong","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Jun","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inn-Chi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4883-9692","authenticated-orcid":false,"given":"Shyi-Jou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4583-6226","authenticated-orcid":false,"given":"I-Ching","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Sheng","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Ting","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuan-Pei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ping","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuu-Jen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3792-9898","authenticated-orcid":false,"given":"Ming-Yuh","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Lin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3231-9764","authenticated-orcid":false,"given":"Wang-Tso","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jfma.2026.09.018_bib1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jfma.2026.09.018_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.braindev.2020.07.012","article-title":"Natural history in spinal muscular atrophy type I in Taiwanese population: a longitudinal study","volume":"43","author":"Ou","year":"2021","journal-title":"Brain Dev"},{"issue":"1","key":"10.1016\/j.jfma.2026.09.018_bib3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.jfma.2026.09.018_bib4","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.tins.2020.11.009","article-title":"Spinal muscular atrophy: in the challenge lies a solution","volume":"44","author":"Wirth","year":"2021","journal-title":"Trends Neurosci"},{"issue":"2","key":"10.1016\/j.jfma.2026.09.018_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017067","article-title":"Carrier screening for spinal muscular atrophy (SMA) in 107,611 pregnant women during the period 2005-2009: a prospective population-based cohort study","volume":"6","author":"Su","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2026.09.018_bib6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jpeds.2017.06.042","article-title":"Presymptomatic diagnosis of spinal muscular atrophy through newborn screening","volume":"190","author":"Chien","year":"2017","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.jfma.2026.09.018_bib7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13023-025-03697-1","article-title":"Newborn screening facilitates early theranostics and improved spinal muscular atrophy outcome: five-year real-world evidence from Taiwan","volume":"20","author":"Wang","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.jfma.2026.09.018_bib8","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.jfma.2026.09.018_bib9","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s00439-006-0156-7","article-title":"Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number","volume":"119","author":"Wirth","year":"2006","journal-title":"Hum Genet"},{"issue":"18","key":"10.1016\/j.jfma.2026.09.018_bib10","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jfma.2026.09.018_bib11","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jfma.2026.09.018_bib12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jfma.2026.09.018_bib13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2102047","article-title":"Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls","volume":"385","author":"Darras","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jfma.2026.09.018_bib14","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jfma.2026.09.018_bib15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"Mercuri","year":"2022","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.jfma.2026.09.018_bib16","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.nmd.2021.03.007","article-title":"Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go","volume":"31","author":"Dangouloff","year":"2021","journal-title":"Neuromuscul Disord"},{"issue":"11","key":"10.1016\/j.jfma.2026.09.018_bib17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.1016\/j.jfma.2026.09.018_bib18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27853","article-title":"Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study","volume":"68","author":"Crawford","year":"2023","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.jfma.2026.09.018_bib19","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jfma.2026.09.018_bib20","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jfma.2026.09.018_bib21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1056\/NEJMoa2410120","article-title":"Risdiplam in presymptomatic spinal muscular atrophy","volume":"393","author":"Finkel","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jfma.2026.09.018_bib22","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/genes14071377","article-title":"Spinal muscular atrophy treatment in patients identified by newborn Screening-A systematic review","volume":"14","author":"Aragon-Gawinska","year":"2023","journal-title":"Genes"},{"issue":"3","key":"10.1016\/j.jfma.2026.09.018_bib23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S2352-4642(22)00342-X","article-title":"Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study","volume":"7","author":"Kariyawasam","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"issue":"6","key":"10.1016\/j.jfma.2026.09.018_bib24","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/jamapediatrics.2024.0492","article-title":"Clinical effectiveness of newborn screening for spinal muscular atrophy: a nonrandomized controlled trial","volume":"178","author":"Schwartz","year":"2024","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jfma.2026.09.018_bib26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejpn.2020.07.001","article-title":"European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy","volume":"28","author":"Kirschner","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"10.1016\/j.jfma.2026.09.018_bib27","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1017\/cjn.2021.125","article-title":"Guidance on gene replacement therapy in spinal muscular atrophy: a Canadian perspective","volume":"49","author":"Oskoui","year":"2022","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.jfma.2026.09.018_bib28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejpn.2024.06.001","article-title":"2024 update: European consensus statement on gene therapy for spinal muscular atrophy","volume":"51","author":"Kirschner","year":"2024","journal-title":"Eur J Paediatr Neurol"},{"issue":"11","key":"10.1016\/j.jfma.2026.09.018_bib29","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/0883073820928784","article-title":"Clinical course in a patient with spinal muscular atrophy type 0 treated with nusinersen and onasemnogene abeparvovec","volume":"35","author":"Matesanz","year":"2020","journal-title":"J Child Neurol"},{"key":"10.1016\/j.jfma.2026.09.018_bib30","article-title":"Onasemnogene abeparvovec gene therapy for treatment of patients with spinal muscular atrophy: updated real-world practical considerations","author":"Proud","year":"2025","journal-title":"J Neuromuscul Dis"},{"issue":"8","key":"10.1016\/j.jfma.2026.09.018_bib31","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J Child Neurol"},{"issue":"2","key":"10.1016\/j.jfma.2026.09.018_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.1016\/j.jfma.2026.09.018_bib33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jfma.2026.09.018_bib34","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"10.1016\/j.jfma.2026.09.018_bib35","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3233\/JND-230122","article-title":"Real-world outcomes in patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy: findings from the RESTORE registry","volume":"11","author":"Servais","year":"2024","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.jfma.2026.09.018_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/2042098619882819","article-title":"Evaluation of quantitative signal detection in EudraVigilance for orphan drugs: possible risk of false negatives","volume":"10","author":"Sardella","year":"2019","journal-title":"Ther Adv Drug Saf"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664626009034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664626009034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:34:49Z","timestamp":1790109289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664626009034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"alternative-id":["S0929664626009034"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2026.09.018","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus on gene therapy for spinal muscular atrophy in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2026.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2026, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}